Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
2HxbTnmCSP39BbCh
